Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340803 | 0.71 | EIF4E (0.42) | ALDH1A1MAPT | |
| SCHEMBL30709186 | 0.68 | MEN1 (0.33) | MEN1KMT2ACYP19A1MAPT | |
| SCHEMBL13203159 | 0.67 | CYP19A1 (0.50) | MEN1KMT2ACYP19A1ESR1ESR2 | |
| SCHEMBL4360069 | 0.67 | CYP19A1 (0.50) | MEN1KMT2ACYP19A1ESR1ESR2 | |
| SCHEMBL18904080 | 0.67 | CYP19A1 (0.50) | MEN1KMT2ACYP19A1ESR1ESR2 | |
| SCHEMBL21974088 | 0.66 | CYP19A1 (0.49) | MEN1KMT2ACYP19A1ESR1ESR2 | |
| SCHEMBL21974098 | 0.66 | CYP19A1 (0.49) | MEN1KMT2ACYP19A1ESR1ESR2 | |
| SCHEMBL13203171 | 0.66 | CYP19A1 (0.52) | MEN1KMT2ACYP19A1ESR1ESR2 | |
| SCHEMBL2754417 | 0.65 | MEN1 (0.46) | MEN1KMT2AADORA1ALDH1A1MAPT | |
| SCHEMBL2754418 | 0.65 | MEN1 (0.46) | MEN1KMT2AADORA1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10038146-B2 | Organic light-emitting compound and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2018-07-31 | — | — | US | disclosed |
| US-10038146-B2 | Organic light-emitting compound and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2018-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10038146-B2 | Organic light-emitting compound and organic electroluminescent device using same | IDO1, IDO2, KYNU | MEN1 2218/4885KMT2A 2669/4885CYP19A1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.